146 related articles for article (PubMed ID: 24737304)
1. The oncolytic adenovirus Δ24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity.
Martinez-Velez N; Xipell E; Jauregui P; Zalacain M; Marrodan L; Zandueta C; Vera B; Urquiza L; Sierrasesúmaga L; Julián MS; Toledo G; Fueyo J; Gomez-Manzano C; Torre W; Lecanda F; Patiño-García A; Alonso MM
J Bone Miner Res; 2014 Oct; 29(10):2287-96. PubMed ID: 24737304
[TBL] [Abstract][Full Text] [Related]
2. The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells.
Berghauser Pont LM; Kleijn A; Kloezeman JJ; van den Bossche W; Kaufmann JK; de Vrij J; Leenstra S; Dirven CM; Lamfers ML
PLoS One; 2015; 10(5):e0127058. PubMed ID: 25993039
[TBL] [Abstract][Full Text] [Related]
3. The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma.
Martínez-Vélez N; Xipell E; Vera B; Acanda de la Rocha A; Zalacain M; Marrodán L; Gonzalez-Huarriz M; Toledo G; Cascallo M; Alemany R; Patiño A; Alonso MM
Clin Cancer Res; 2016 May; 22(9):2217-25. PubMed ID: 26603261
[TBL] [Abstract][Full Text] [Related]
4. The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.
Kleijn A; Kloezeman J; Treffers-Westerlaken E; Fulci G; Leenstra S; Dirven C; Debets R; Lamfers M
PLoS One; 2014; 9(5):e97495. PubMed ID: 24866126
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic concentrations of anti-epileptic drugs do not inhibit the activity of the oncolytic adenovirus Delta24-RGD in malignant glioma.
de Jonge J; Berghauser Pont LM; Idema S; Kloezeman JJ; Noske D; Dirven CM; Lamfers ML
J Gene Med; 2013; 15(3-4):134-41. PubMed ID: 23606319
[TBL] [Abstract][Full Text] [Related]
6. Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus delta24-RGD to infiltrating glioma.
Balvers RK; Belcaid Z; van den Hengel SK; Kloezeman J; de Vrij J; Wakimoto H; Hoeben RC; Debets R; Leenstra S; Dirven C; Lamfers ML
Viruses; 2014 Aug; 6(8):3080-96. PubMed ID: 25118638
[TBL] [Abstract][Full Text] [Related]
7. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas.
Yong RL; Shinojima N; Fueyo J; Gumin J; Vecil GG; Marini FC; Bogler O; Andreeff M; Lang FF
Cancer Res; 2009 Dec; 69(23):8932-40. PubMed ID: 19920199
[TBL] [Abstract][Full Text] [Related]
8. Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin.
Yoon AR; Kim JH; Lee YS; Kim H; Yoo JY; Sohn JH; Park BW; Yun CO
Hum Gene Ther; 2006 Apr; 17(4):379-90. PubMed ID: 16610926
[TBL] [Abstract][Full Text] [Related]
9. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
Raki M; Särkioja M; Desmond RA; Chen DT; Bützow R; Hemminki A; Kanerva A
Gynecol Oncol; 2008 Jan; 108(1):166-72. PubMed ID: 17950450
[TBL] [Abstract][Full Text] [Related]
11. Intravenous administration of the conditionally replicative adenovirus Ad5-Delta24RGD induces regression of osteosarcoma lung metastases.
Graat HC; van Beusechem VW; Schagen FH; Witlox MA; Kleinerman ES; Helder MN; Gerritsen WR; Kaspers GJ; Wuisman PI
Mol Cancer; 2008 Jan; 7():9. PubMed ID: 18215325
[TBL] [Abstract][Full Text] [Related]
12. Potent antitumor effect of interleukin-24 gene in the survivin promoter and retinoblastoma double-regulated oncolytic adenovirus.
Zhang KJ; Wang YG; Cao X; Zhong SY; Wei RC; Wu YM; Yue XT; Li GC; Liu XY
Hum Gene Ther; 2009 Aug; 20(8):818-30. PubMed ID: 19320563
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer.
Ganesh S; Gonzalez-Edick M; Gibbons D; Ge Y; VanRoey M; Robinson M; Jooss K
Cancer Gene Ther; 2009 May; 16(5):383-92. PubMed ID: 19011598
[TBL] [Abstract][Full Text] [Related]
14. Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells.
Hasei J; Sasaki T; Tazawa H; Osaki S; Yamakawa Y; Kunisada T; Yoshida A; Hashimoto Y; Onishi T; Uno F; Kagawa S; Urata Y; Ozaki T; Fujiwara T
Mol Cancer Ther; 2013 Mar; 12(3):314-25. PubMed ID: 23315976
[TBL] [Abstract][Full Text] [Related]
15. Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory.
Martinez-Velez N; Laspidea V; Zalacain M; Labiano S; García-Moure M; Puigdelloses M; Marrodan L; Gonzalez-Huarriz M; Herrador G; de la Nava D; Ausejo-Mauleon I; Fueyo J; Gomez-Manzano C; Patiño-García A; Alonso MM
Mol Cancer Ther; 2022 Mar; 21(3):471-480. PubMed ID: 34965961
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma.
Kondo N; Tsukuda M; Kimura M; Fujita K; Sakakibara A; Takahashi H; Ishiguro Y; Toth G; Matsuda H
Oncol Rep; 2010 Feb; 23(2):355-63. PubMed ID: 20043095
[TBL] [Abstract][Full Text] [Related]
17. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
[TBL] [Abstract][Full Text] [Related]
18. An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer.
Zhong S; Yu D; Wang Y; Qiu S; Wu S; Liu XY
Acta Oncol; 2010; 49(1):91-9. PubMed ID: 19734998
[TBL] [Abstract][Full Text] [Related]
19. Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.
Workenhe ST; Pol JG; Lichty BD; Cummings DT; Mossman KL
Cancer Immunol Res; 2013 Nov; 1(5):309-19. PubMed ID: 24777969
[TBL] [Abstract][Full Text] [Related]
20. Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin.
Graat HC; Witlox MA; Schagen FH; Kaspers GJ; Helder MN; Bras J; Schaap GR; Gerritsen WR; Wuisman PI; van Beusechem VW
Br J Cancer; 2006 Jun; 94(12):1837-44. PubMed ID: 16736005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
